普洱茶素&#x02164;~&#x02166;对4种乳腺癌细胞作用研究

杨锐; 赵兴平; 何明婕; 刘敏; 罗蓉; 陈川龙; 潘淑康; 丁章贵

doi:10.13305/j.cnki.jts.2024.03.004

PDF(3445 KB)

茶叶科学 ›› 2024, Vol. 44 ›› Issue (3) : 501-514. DOI: 10.13305/j.cnki.jts.2024.03.004

研究报告

普洱茶素Ⅴ~Ⅶ对4种乳腺癌细胞作用研究

杨锐^1,2,6, 赵兴平^1,2,6, 何明婕^1,2,6, 刘敏^1,2,6, 罗蓉^1,2,6, 陈川龙^5,6, 潘淑康^1,2,6,*, 丁章贵^1,2,3,4,6,*

作者信息 +

Study on the Effects of Puerins Ⅴ-Ⅶ on Four Kinds of Breast Cancer Cells

YANG Rui^1,2,6, ZHAO Xingping^1,2,6, HE Mingjie^1,2,6, LIU Min^1,2,6, LUO Rong^1,2,6, CHEN Chuanlong^5,6, PAN Shukang^1,2,6,*, DING Zhanggui^1,2,3,4,6,*

Author information +

文章历史 +

摘要

普洱茶素（Puerins）是从普洱熟茶中分离得到的儿茶素衍生物,是一类结构独特的含氮多酚化合物。开展普洱茶素Ⅴ~Ⅶ抗乳腺癌细胞作用的研究,以4种不同受体表型的乳腺癌细胞株为模型,进行噻唑蓝（MTT）比色试验、蛋白质组学检测及细胞凋亡检测等试验。结果表明,普洱茶素Ⅴ、Ⅵ和Ⅶ等3个单体化合物对4种乳腺癌细胞都有显著的抑制作用;蛋白质组学分析发现,普洱茶素干预后乳腺癌细胞表达产生差异的蛋白主要集中于代谢通路,其次是癌症通路和黏附斑信号通路;细胞凋亡检测发现3个普洱茶素化合物均可诱导MDA-MB-231细胞的凋亡。本研究报道了普洱茶素Ⅴ~Ⅶ的抗乳腺癌细胞活性及初步作用机制,为研究普洱熟茶抗癌活性物质提供基础信息。

Abstract

Puerins, a kind of nitrogen-containing polyphenol compound with unique structure, is a kind of catechin derivative first isolated from ripened Pu-erh tea. In this paper, the effects of puerins Ⅴ-Ⅶ on breast cancer cells were studied. Four breast cancer cell lines with different receptor phenotypes were used as models, and MTT assay, proteomics detection and apoptosis detection were carried out. The results show that all puerins Ⅴ, Ⅵ and Ⅶ had obvious inhibitory effects on the four kinds of breast cancer cells. Proteomics analysis indicates that the differentially expressed proteins were mainly concentrated in the metabolic pathway, followed by cancer pathway and adhesion spot signal pathway under the intervention of puerins Ⅴ-Ⅶ. Apoptosis detection demonstrates that all three puerins compounds could induce the apoptosis of MDA-MB-231 cells. This study first reported the anti-breast cancer activity and preliminary mechanism of puerins Ⅴ-Ⅶ, which provided basic information for studying the anti-cancer active substances of ripened Pu-erh tea.

导出引用

杨锐, 赵兴平, 何明婕, 刘敏, 罗蓉, 陈川龙, 潘淑康, 丁章贵. 普洱茶素Ⅴ~Ⅶ对4种乳腺癌细胞作用研究[J]. 茶叶科学. 2024, 44(3): 501-514 https://doi.org/10.13305/j.cnki.jts.2024.03.004

YANG Rui, ZHAO Xingping, HE Mingjie, LIU Min, LUO Rong, CHEN Chuanlong, PAN Shukang, DING Zhanggui. Study on the Effects of Puerins Ⅴ-Ⅶ on Four Kinds of Breast Cancer Cells[J]. Journal of Tea Science. 2024, 44(3): 501-514 https://doi.org/10.13305/j.cnki.jts.2024.03.004

中图分类号： S571.1 R737.9

参考文献

[1] 顾睿, 李瑞明, 张兰兰, 等. 普洱茶化学成分及药理研究进展[J]. 天津药学, 2011, 23(1): 47-51.
Gu R, Li R M, Zhang L L, et al.Advances in study on chemical composition and pharmacological properties of pu-erh tea[J]. Tianjin Pharmacy, 2011, 23(1): 47-51.
[2] 顾小盼, 潘勃, 吴臻, 等. 普洱茶药理作用研究进展[J]. 中国中药杂志, 2017, 42(11): 2038-2041.
Gu X P, Pan B, Wu Z, et al.Progress in research for pharmacological effects of pu-erh tea[J]. China Journal of Chinese Materia Medica, 2017, 42(11): 2038-2041.
[3] 孟宪钰, 付亚轩, 李明超, 等. 普洱熟茶化学成分研究进展[J]. 食品与发酵工业, 2019, 45(12): 289-294.
Meng X Y, Fu Y X, Li M C, et al.Advance in the study on the chemical composition of pu-erh tea[J]. Food and Fermentation Industries, 2019, 45(12): 289-294.
[4] Zhou Z H, Zhang Y J, Xu M, et al.Puerins A and B, two new 8-C substituted flavan-3-ols from pu-er tea[J]. Journal of Agricultural and Food Chemistry, 2005, 53(22): 8614-8617.
[5] 东方, 杨子银, 何普明, 等. 普洱茶抗氧化活性成分的LC-MS分析[J]. 中国食品学报, 2008, 8(2): 133-141.
Dong F, Yang Z Y, He P M, et al.Liquid chromatographic-mass spectrometric analysis of antioxidant compounds from pu-erh tea[J]. Journal of Chinese Institute of Food Science and Technology, 2008, 8(2): 133-141.
[6] Wang W, Zhang L, Wang S, et al.8-C N-ethyl-2-pyrrolidinone substituted flavan-3-ols as the marker compounds of Chinese dark teas formed in the post-fermentation process provide significant antioxidative activity[J]. Food Chemistry, 2014, 152: 539-545.
[7] 顾小盼, 吴臻, 靳凤玉, 等. 普洱茶素Ⅰ改善糖脂代谢紊乱的药效评价及作用机制研究[J]. 中国中药杂志, 2018, 43(11): 2339-2344.
Gu X P, Wu Z, Jin F Y, et al.Efficacy and mechanism of puerin Ⅰ in improving disorder of glycolipid metabolism in ApoE-/- mice[J]. China Journal of Chinese Materia Medica, 2018, 43(11): 2339-2344.
[8] 王鑫玉, 赵一慕, 高云, 等. 普洱茶素Ⅱ改善高脂血症ApoE-/-小鼠动脉粥样硬化作用机制研究[J]. 中草药, 2023, 54(4): 1157-1163.
Wang X Y, Zhao Y M, Gao Y, et al.Mechanism of puerin Ⅱ on improving atherosclerosis in ApoE-/- mice with hyperlipidemia[J]. Chinese Traditional and Herbal Drugs, 2023, 54(4): 1157-1163.
[9] Gu X P, Meng Y X, Jin F Y, et al.Puerin III alleviates glucose and lipid metabolism disorders in high-fat high-sucrose diet-induced hyperlipidemic and hyperglycemic ApoE-/-mice[J]. Journal of Functional Foods, 2022, 93: 105085. doi: 10.1016/j.jff.2022.105085.
[10] Ye F, Dewanjee S, Li Y H, et al.Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer[J]. Molecular Cancer, 2023, 22(1): 105. doi: 10.1186/s12943-023-01805-y.
[11] Siegel R L, Miller K D, Wagle N S, et al.Cancer statistics, 2023[J]. CA: A Cancer Journal for Clinicians, 2023, 73(1): 17-48.
[12] Feng Y X, Spezia M, Huang S F, et al.Breast cancer development and progression: risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis[J]. Genes & Diseases, 2018, 5(2): 77-106.
[13] Sviderskiy V O, Blumenberg L, Gorodetsky E, et al.Hyperactive CDK2 activity in basal-like breast cancer imposes a genome integrity liability that can be exploited by targeting DNA polymerase ε[J]. Molecular Cell, 2020, 80(4): 682-698.
[14] 陈安莉, 沈浩元, 舒王. 三阴性乳腺癌新辅助治疗的临床研究进展[J]. 现代肿瘤医学, 2023, 31(3): 566-571.
Chen A L, Shen H Y, Shu W.Neoadjuvant therapy for triple negative breast cancer: clinical progress[J]. Modern Oncology, 2023, 31(3): 566-571.
[15] Xie J, Yu H S, Song S, et al.Pu-erh tea water extract mediates cell cycle arrest and apoptosis in MDA-MB-231 human breast cancer cells[J]. Frontiers in Pharmacology, 2017, 8: 190. doi: 10.3389/fphar.2017.00190.
[16] 杨潇, 龙汉安, 肖秀丽. 不同分子亚型乳腺癌临床特征及治疗策略研究进展[J]. 牡丹江医学院学报, 2013, 34(2): 76-78.
Yang X, Long H A, Xiao X L.Research progress on clinical characteristics and treatment strategies of different molecular subtypes of breast cancer[J]. Journal of Mudanjing Medical University, 2013, 34(2): 76-78.
[17] 王烈, 黎成金. 乳腺癌治疗方法的变迁[J]. 中国临床医生, 2011, 39(7): 12-14.
Wang L, Li C J.Changes of treatment methods for breast cancer[J]. Chinese Journal for Clinicians, 2011, 39(7): 12-14.
[18] Zhao L J, Jia S T, Tang W R, et al.Pu-erh tea inhibits tumor cell growth by down-regulating mutant p53[J]. International Journal of Molecular Sciences, 2011, 12(11): 7581-7593.
[19] Zhao H, Zhang M, Zhao L, et al.Changes of constituents and activity to apoptosis and cell cycle during fermentation of tea[J]. International Journal of Molecular Sciences, 2011, 12(3): 1862-1875.
[20] 韩莎莎, 高雄, 林晓蓉, 等. 普洱茶挥发性组分的抗癌、抗炎功能特性[J]. 食品工业科技, 2019, 40(3): 97-105.
Han S S, Gao X, Lin X R, et al.Anti-cancer and anti-inflammatory activities of volatile components from pu-erh tea[J]. Science and Technology of Food Industry. 2019, 40(3): 97-105.
[21] 赵航, 盛婧雪, 李洪广, 等. 普洱茶提取物对宫颈癌hela细胞的诱导凋亡作用[J]. 中国生物制品学杂志, 2011, 24(2): 137-140.
Zhao H, Sheng J X, Li H G, et al.Induction of apoptosis of hela cells with pu-erh tea extracts[J]. Chinese Journal of Biologicals, 2011, 24(2): 137-140.
[22] Zhao X, Qian Y, Zou Y L, et al.Pu-erh tea has in vitro anticancer activity in TCA8113 cells and preventive effects on buccal mucosa cancer in U14 cells injected mice in vivo[J]. Nutrition and Cancer, 2014, 66(6): 1059-1069.